
Ascendis Pharma A/S ASND
$ 240.8
-0.53%
Annual report 2025
added 02-28-2026
Ascendis Pharma A/S Interest Expense 2011-2026 | ASND
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.6 M | 65.5 M | 44.1 M | 30.7 M | 3.91 M | 1.92 M | 1.22 M | 127 K | 97 K | 5 K | 6 K | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 80.6 M | 5 K | 20.7 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals
APLS
|
-133 K | $ 20.15 | -2.68 % | $ 2.54 B | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Axsome Therapeutics
AXSM
|
-15.9 M | $ 163.7 | -1.61 % | $ 8.14 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.72 | -2.75 % | $ 1.11 B | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Certara
CERT
|
6.34 M | $ 7.16 | 1.49 % | $ 1.15 B | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
399 K | $ 25.91 | -3.56 % | $ 694 M | ||
|
Codexis
CDXS
|
-10.4 M | $ 0.99 | -3.28 % | $ 72.7 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
25.7 M | $ 24.0 | 0.5 % | $ 2.93 B | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
1.26 M | $ 3.19 | -4.64 % | $ 1.14 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.96 M | $ 28.78 | -1.44 % | $ 1.67 B | ||
|
Champions Oncology
CSBR
|
73 K | $ 6.0 | -1.15 % | $ 82 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Cellectis S.A.
CLLS
|
371 K | $ 3.67 | -3.42 % | $ 116 M | ||
|
Alector
ALEC
|
13.2 M | $ 2.11 | -4.75 % | $ 217 M | ||
|
KalVista Pharmaceuticals
KALV
|
4.81 M | $ 15.68 | -2.4 % | $ 779 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
48 K | $ 4.17 | 0.24 % | $ 296 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
7 K | $ 14.27 | 2.44 % | $ 5.92 B |